Jing-Ping Liou

2023

6-Regioisomeric 5,8-quinolinediones as potent CDC25 inhibitors against colorectal cancers

Narwanti, I., Yu, Z. Y., Sethy, B., Lai, M. J., Lee, H. Y., Olena, P., Lee, S. B. & Liou, J. P., 10月 2023, 於: European Journal of Medicinal Chemistry. 258, 115505.

研究成果: 雜誌貢獻 › 文章 › 同行評審

Design, synthesis, and biological activity of dual monoamine oxidase A and heat shock protein 90 inhibitors, N-Methylpropargylamine-conjugated 4-isopropylresorcinol for glioblastoma

Tseng, H. J., Banerjee, S., Qian, B., Lai, M. J., Wu, T. Y., Hsu, T. I., Lin, T. E., Hsu, K. C., Chuang, K. H., Liou, J. P. & Shih, J. C., 8月 2023, 於: European Journal of Medicinal Chemistry. 256, 115459.

研究成果: 雜誌貢獻 › 文章 › 同行評審

1 引文斯高帕斯（Scopus）

Rational design of synthetically tractable HDAC6/HSP90 dual inhibitors to destroy immune-suppressive tumor microenvironment

Wu, T. Y., Chen, M., Chen, I. C., Chen, Y. J., Chen, C. Y., Wang, C. H., Cheng, J. J., Nepali, K., Chuang, K. H. & Liou, J. P., 4月 2023, 於: Journal of Advanced Research. 46, p. 159-171

研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取

4 引文斯高帕斯（Scopus）

Rationally designed donepezil-based hydroxamates modulate Sig-1R and HDAC isoforms to exert anti-glioblastoma effects

Nepali, K., Wu, A. C., Lo, W. L., Chopra, B., Lai, M. J., Chuang, J. Y. & Liou, J. P., 2月 2023, 於: European Journal of Medicinal Chemistry. 248, 115054.

研究成果: 雜誌貢獻 › 文章 › 同行評審

2022

2,6-Difluorobenzamide derivatives as store-operated calcium channel (SOC) inhibitors

Wang, Y. S., Yeh, T. K., Chang, W. C., Liou, J. P., Liu, Y. M. & Huang, W. C., 12月 5 2022, 於: European Journal of Medicinal Chemistry. 243, 114773.

研究成果: 雜誌貢獻 › 文章 › 同行評審

Accommodation of ring C expanded deoxyvasicinone in the HDAC inhibitory pharmacophore culminates into a tractable anti-lung cancer agent and pH-responsive nanocarrier

Sharma, R., Chatterjee, E., Mathew, J., Sharma, S., Rao, N. V., Pan, C. H., Lee, S. B., Dhingra, A., Grewal, A. S., Liou, J. P., Guru, S. K. & Nepali, K., 10月 5 2022, 於: European Journal of Medicinal Chemistry. 240, 114602.

研究成果: 雜誌貢獻 › 文章 › 同行評審

2 引文斯高帕斯（Scopus）

A Potent Histone Deacetylase Inhibitor MPT0E028 Mitigates Emphysema Severity via Components of the Hippo Signaling Pathway in an Emphysematous Mouse Model

Yeh, L-Y., Fang, Y-T., Lee, H-S., Liu, C-H., Chen, Y-Y., Lo, Y-C., Laiman, V., Liou, J-P., Chung, K. F., Chuang, H-C. & Lin, C-H., 5月 2022, 於: Frontiers in Medicine. 9, 794025.

研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取

HDAC6 involves in regulating the lncRNA-microRNA-mRNA network to promote the proliferation of glioblastoma cells

Wu, A. C., Yang, W. B., Chang, K. Y., Lee, J. S., Liou, J. P., Su, R. Y., Cheng, S. M., Hwang, D. Y., Kikkawa, U., Hsu, T. I., Wang, C. Y., Chang, W. C., Chen, P. Y. & Chuang, J. Y., 12月 2022, 於: Journal of Experimental and Clinical Cancer Research. 41, 1, 47.

研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取

7 引文斯高帕斯（Scopus）

N-Methylpropargylamine-Conjugated Hydroxamic Acids as Dual Inhibitors of Monoamine Oxidase A and Histone Deacetylase for Glioma Treatment

Mehndiratta, S., Qian, B., Chuang, J. Y., Liou, J. P. & Shih, J. C., 2月 2022, 於: Journal of Medicinal Chemistry. 65, 3, p. 2208-2224 17 p.

研究成果: 雜誌貢獻 › 文章 › 同行評審

7 引文斯高帕斯（Scopus）

Structural compositions and biological activities of cell wall polysaccharides in the rhizome, stem, and leaf of Polygonatum odoratum (Mill.) Druce

Li, J., Hsiung, S. Y., Kao, M. R., Xing, X., Chang, S. C., Wang, D., Hsieh, P. Y., Liang, P. H., Zhu, Z., Cheng, T. J. R., Shie, J. J., Liou, J. P., Abbott, D. W., Kwon, S. W. & Hsieh, Y. S. Y., 11月 2022, 於: Carbohydrate Research. 521, 108662.

研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取

1 引文斯高帕斯（Scopus）

2021

A novel dual HDAC and HSP90 inhibitor, MPT0G449, downregulates oncogenic pathways in human acute leukemia in vitro and in vivo

Wu, Y. W., Chao, M. W., Tu, H. J., Chen, L. C., Hsu, K. C., Liou, J. P., Yang, C. R., Yen, S. C., HuangFu, W. C. & Pan, S. L., 5月 2021, 於: Oncogenesis. 10, 5, 39.

研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取

15 引文斯高帕斯（Scopus）

A novel histone deacetylase inhibitor MPT0L184 dysregulates cell-cycle checkpoints and initiates unscheduled mitotic signaling

Chang, T. Y., Nepali, K., Chen, Y. Y., Yang, Y. C. S. H., Hsu, K. C., Yen, Y., Pan, S. L., Liou, J. P. & Lee, S. B., 6月 2021, 於: Biomedicine and Pharmacotherapy. 138, 111485.

研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取

4 引文斯高帕斯（Scopus）

CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition

Singh, A., Chang, T. Y., Kaur, N., Hsu, K. C., Yen, Y., Lin, T. E., Lai, M. J., Lee, S. B. & Liou, J. P., 4月 5 2021, 於: European Journal of Medicinal Chemistry. 215, 113169.

研究成果: 雜誌貢獻 › 文章 › 同行評審

14 引文斯高帕斯（Scopus）

Combining an autophagy inhibitor, mpt0l145, with abemaciclib is a new therapeutic strategy in gbm treatment

Hsieh, T. H., Liang, M. L., Zheng, J. H., Lin, Y. C., Yang, Y. C. S. H., Vo, T. H., Liou, J. P., Yen, Y. & Chen, C. H., 12月 1 2021, 於: Cancers. 13, 23, 6117.

研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取

2 引文斯高帕斯（Scopus）

Effect of 3-subsitution of quinolinehydroxamic acids on selectivity of histone deacetylase isoforms

Mehndiratta, S., Chen, M. C., Chao, Y. H., Lee, C. H., Liou, J. P., Lai, M. J. & Lee, H. Y., 1月 1 2021, 於: Journal of Enzyme Inhibition and Medicinal Chemistry. 36, 1, p. 74-84 11 p.

研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取

2 引文斯高帕斯（Scopus）

Erratum: TIMP3 expression associates with prognosis in colorectal cancer and its novel arylsulfonamide inducer, MPT0B390, inhibits tumor growth, metastasis and angiogenesis: Erratum

Huang, H. L., Liu, Y. M., Sung, T. Y., Huang, T. C., Cheng, Y. W., Liou, J. P. & Pan, S. L., 1月 1 2021, 於: Theranostics. 11, 5, p. 2079 1 p.

研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取

1 引文斯高帕斯（Scopus）

Histone deacetylase 6 acts upstream of DNA damage response activation to support the survival of glioblastoma cells

Yang, W. B., Wu, A. C., Hsu, T. I., Liou, J. P., Lo, W. L., Chang, K. Y., Chen, P. Y., Kikkawa, U., Yang, S. T., Kao, T. J., Chen, R. M., Chang, W. C., Ko, C. Y. & Chuang, J. Y., 10月 2021, 於: Cell Death and Disease. 12, 10, 884.

研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取

7 引文斯高帕斯（Scopus）

Installation of Pargyline, a LSD1 Inhibitor, in the HDAC Inhibitory Template Culminated in the Identification of a Tractable Antiprostate Cancer Agent

Ojha, R., Chen, I. C., Hsieh, C. M., Nepali, K., Lai, R. W., Hsu, K. C., Lin, T. E., Pan, S. L., Chen, M. C. & Liou, J. P., 2021, (接受/付印) 於: Journal of Medicinal Chemistry. 64, 24, p. 17824-17845 22 p.

研究成果: 雜誌貢獻 › 文章 › 同行評審

8 引文斯高帕斯（Scopus）

Optimization and development of selective histone deacetylase inhibitor (Mpt0b291)-loaded albumin nanoparticles for anticancer therapy

Putri, A. D., Chen, P. S., Su, Y. L., Lin, J. P., Liou, J. P. & Hsieh, C. M., 10月 2021, 於: Pharmaceutics. 13, 10, 1728.

研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取

6 引文斯高帕斯（Scopus）

Pragmatic recruitment of memantine as the capping group for the design of HDAC inhibitors: A preliminary attempt to unravel the enigma of glioblastoma

Nepali, K., Hsu, T. I., Hsieh, C. M., Lo, W. L., Lai, M. J., Hsu, K. C., Lin, T. E., Chuang, J. Y. & Liou, J. P., 5月 5 2021, 於: European Journal of Medicinal Chemistry. 217, 113338.

研究成果: 雜誌貢獻 › 文章 › 同行評審

12 引文斯高帕斯（Scopus）

Ring-opening of five-membered heterocycles conjugated 4-isopropylresorcinol scaffold-based benzamides as HSP90 inhibitors suppressing tumor growth in vitro and in vivo

Liu, Y. M., Tu, H. J., Wu, C. H., Lai, M. J., Yu, S. C., Chao, M. W., Wu, Y. W., Teng, C. M., Pan, S. L. & Liou, J. P., 7月 5 2021, 於: European Journal of Medicinal Chemistry. 219, 113428.

研究成果: 雜誌貢獻 › 文章 › 同行評審

7 引文斯高帕斯（Scopus）

Suppression of extracellular vesicle VEGF-C-mediated lymphangiogenesis and pancreatic cancer early dissemination by a selective HDAC1/2 inhibitor

Wang, C. A., Li, C. F., Huang, R. C., Li, Y. H., Liou, J. P. & Tsai, S. J., 9月 2021, 於: Molecular Cancer Therapeutics. 20, 9, p. 1550-1560 11 p.

研究成果: 雜誌貢獻 › 文章 › 同行評審

8 引文斯高帕斯（Scopus）

2020

CK1δ as a potential therapeutic target to treat bladder cancer

Lin, Y. C., Chen, M. C., Hsieh, T. H., Liou, J. P. & Chen, C. H., 4月 15 2020, 於: Aging. 12, 7, p. 5764-5780 17 p.

研究成果: 雜誌貢獻 › 文章 › 同行評審

8 引文斯高帕斯（Scopus）

Design, synthesis, and evaluation of N-phenyl-4-(2-phenylsulfonamido)-benzamides as microtubule-targeting agents in drug-resistant cancer cells, displaying HDAC inhibitory response

Wu, W. C., Liu, Y. M., Lin, M. H., Liao, Y. H., Lai, M. J., Chuang, H. Y., Hung, T. Y., Chen, C. H. & Liou, J. P., 4月 15 2020, 於: European Journal of Medicinal Chemistry. 192, p. 112158 112158.

研究成果: 雜誌貢獻 › 文章 › 同行評審

10 引文斯高帕斯（Scopus）

Fluoropyrimidin-2,4-dihydroxy-5-isopropylbenzamides as antitumor agents against CRC and NSCLC cancer cells

Wu, W. C., Liu, Y. M., Liao, Y. H., Hsu, K. C., Lien, S. T., Chen, I. C., Lai, M. J., Li, Y. H., Pan, S. L., Chen, M. C. & Liou, J. P., 10月 1 2020, 於: European Journal of Medicinal Chemistry. 203, 112540.

研究成果: 雜誌貢獻 › 文章 › 同行評審

4 引文斯高帕斯（Scopus）

HDAC inhibitor protects chronic cerebral hypoperfusion and oxygen-glucose deprivation injuries via H3K14 and H4K5 acetylation-mediated BDNF expression

Fang, Y-C., Chan, L., Liou, J-P., Tu, Y-K., Lai, M-J., Chen, C-I., Vidyanti, A. N., Lee, H-Y. & Hu, C-J., 6月 1 2020, 於: Journal of Cellular and Molecular Medicine. 24, 12, p. 6966-6977 12 p.

研究成果: 雜誌貢獻 › 文章 › 同行評審

7 引文斯高帕斯（Scopus）

Histone deacetylase inhibitor MPT0B291 suppresses glioma growth in vitro and in vivo partially through acetylation of p53

Buyandelger, B., Bar, E. E., Hung, K. S., Chen, R. M., Chiang, Y. H., Liou, J. P., Huang, H. M. & Wang, J. Y., 2020, 於: International Journal of Biological Sciences. 16, 16, p. 3184-3199 16 p.

研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取

10 引文斯高帕斯（Scopus）

Increased activation of HDAC1/2/6 and Sp1 underlies therapeutic resistance and tumor growth in glioblastoma

Yang, W-B., Hsu, C-C., Hsu, T-I., Liou, J-P., Chang, K-Y., Chen, P-Y., Liu, J-J., Yang, S-T., Wang, J-Y., Yeh, S-H., Chen, R-M., Chang, W-C. & Chuang, J-Y., 10月 1 2020, 於: Neuro-Oncology. 22, 10, p. 1439-1451 13 p.

研究成果: 雜誌貢獻 › 文章 › 同行評審

56 引文斯高帕斯（Scopus）

Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo

Ojha, R., Nepali, K., Chen, C. H., Chuang, K. H., Wu, T. Y., Lin, T. E., Hsu, K. C., Chao, M. W., Lai, M. J., Lin, M. H., Huang, H. L., Chang, C. D., Pan, S. L., Chen, M. C. & Liou, J. P., 3月 15 2020, 於: European Journal of Medicinal Chemistry. 190, 112086.

研究成果: 雜誌貢獻 › 文章 › 同行評審

22 引文斯高帕斯（Scopus）

N-alkyl-hydroxybenzoyl anilide hydroxamates as dual inhibitors of HDAC and HSP90, downregulating IFN-γ induced PD-L1 expression

Mehndiratta, S., Lin, M. H., Wu, Y. W., Chen, C. H., Wu, T. Y., Chuang, K. H., Chao, M. W., Chen, Y. Y., Pan, S. L., Chen, M. C. & Liou, J. P., 1月 1 2020, 於: European Journal of Medicinal Chemistry. 185, p. 111725 111725.

研究成果: 雜誌貢獻 › 文章 › 同行評審

37 引文斯高帕斯（Scopus）

Protective effects of 10,11-dihydro-5H-dibenzo[b,f]azepine hydroxamates on vascular cognitive impairment

Kaur, N., Fang, Y. C., Lee, H. Y., Singh, A., Nepali, K., Lin, M. H., Yeh, T. K., Lai, M. J., Chan, L., Tu, Y. K., Banerjee, S., Hu, C. J. & Liou, J. P., 2月 1 2020, 於: European Journal of Medicinal Chemistry. 187, 111915.

研究成果: 雜誌貢獻 › 文章 › 同行評審

10 引文斯高帕斯（Scopus）

Purine/purine isoster based scaffolds as new derivatives of benzamide class of HDAC inhibitors

Nepali, K., Chang, T. Y., Lai, M. J., Hsu, K. C., Yen, Y., Lin, T. E., Lee, S. B. & Liou, J. P., 6月 15 2020, 於: European Journal of Medicinal Chemistry. 196, 112291.

研究成果: 雜誌貢獻 › 文章 › 同行評審

29 引文斯高帕斯（Scopus）

Synthesis and biological evaluation of 2-quinolineacrylamides

Wang, S. W., Lin, M. H., Hsu, F. C., Chen, M. C., Liou, J. P., Liu, Y. T., Chen, S. S. & Lee, H. Y., 2月 1 2020, 於: Bioorganic and Medicinal Chemistry. 28, 3, p. 115250 115250.

研究成果: 雜誌貢獻 › 文章 › 同行評審

5 引文斯高帕斯（Scopus）

2019

1-Arylsulfonyl indoline-benzamides as a new antitubulin agents, with inhibition of histone deacetylase

Lai, M. J., Ojha, R., Lin, M. H., Liu, Y. M., Lee, H. Y., Lin, T. E., Hsu, K. C., Chang, C. Y., Chen, M. C., Nepali, K., Chang, J. Y. & Liou, J. P., 1月 15 2019, 於: European Journal of Medicinal Chemistry. 162, p. 612-630 19 p.

研究成果: 雜誌貢獻 › 文章 › 同行評審

30 引文斯高帕斯（Scopus）

Amide-tethered quinoline-resorcinol conjugates as a new class of HSP90 inhibitors suppressing the growth of prostate cancer cells

Nepali, K., Lin, M. H., Chao, M. W., Peng, S. J., Hsu, K. C., Eight Lin, T., Chen, M. C., Lai, M. J., Pan, S. L. & Liou, J. P., 10月 1 2019, 於: Bioorganic Chemistry. 91, 103119.

研究成果: 雜誌貢獻 › 文章 › 同行評審

10 引文斯高帕斯（Scopus）

Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo

Hsieh, Y. L., Tu, H. J., Pan, S. L., Liou, J. P. & Yang, C. R., 6月 1 2019, 於: Biochimica et Biophysica Acta - Molecular Cell Research. 1866, 6, p. 992-1003 12 p.

研究成果: 雜誌貢獻 › 文章 › 同行評審

30 引文斯高帕斯（Scopus）

Combination treatment strategy for pancreatic cancer involving the novel HDAC inhibitor MPT0E028 with a MEK inhibitor beyond K-Ras status

Chao, M. W., Chang, L. H., Tu, H. J., Chang, C. D., Lai, M. J., Chen, Y. Y., Liou, J. P., Teng, C. M. & Pan, S. L., 5月 29 2019, 於: Clinical Epigenetics. 11, 1, p. 85 85.

研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取

18 引文斯高帕斯（Scopus）

MPT0G413, A novel HDAC6-selective inhibitor, and bortezomib synergistically exert anti-tumor activity in multiple myeloma cells

Huang, F. I., Wu, Y. W., Sung, T. Y., Liou, J. P., Lin, M. H., Pan, S. L. & Yang, C. R., 1月 1 2019, 於: Frontiers in Oncology. 9, APR, p. 249 249.

研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取

18 引文斯高帕斯（Scopus）

MPT0G612, a novel HDAC6 inhibitor, induces apoptosis and suppresses ifn-Γ-induced programmed death-ligand 1 in human colorectal carcinoma cells

Chen, M. C., Lin, Y. C., Liao, Y. H., Liou, J. P. & Chen, C. H., 10月 2019, 於: Cancers. 11, 10, 1617.

研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取

23 引文斯高帕斯（Scopus）

Synthesis and evaluation of novel 7H-pyrrolo-[2,3-d]pyrimidine derivatives as potential anticancer agents

Liu, Y-M., Chen, C-H., Yeh, T-K. & Liou, J-P., 2月 21 2019, 於: Future Medicinal Chemistry.

研究成果: 雜誌貢獻 › 文章 › 同行評審

9 引文斯高帕斯（Scopus）

Targeting autophagy by MPT0L145, a highly potent pik3c3 inhibitor, provides synergistic interaction to targeted or chemotherapeutic agents in cancer cells

Chen, C. H., Hsieh, T. H., Lin, Y. C., Liu, Y. R., Liou, J. P. & Yen, Y., 9月 2019, 於: Cancers. 11, 9, 1345.

研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取

11 引文斯高帕斯（Scopus）

TIMP3 expression associates with prognosis in colorectal cancer and its novel arylsulfonamide inducer, MPT0B390, inhibits tumor growth, metastasis and angiogenesis

Huang, H. L., Liu, Y. M., Sung, T. Y., Huang, T. C., Cheng, Y. W., Liou, J. P. & Pan, S. L., 1月 1 2019, 於: Theranostics. 9, 22, p. 6676-6689 14 p.

研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取

22 引文斯高帕斯（Scopus）

2018

(N-Hydroxycarbonylbenylamino)quinolines as Selective Histone Deacetylase 6 Inhibitors Suppress Growth of Multiple Myeloma in Vitro and in Vivo

Lee, H. Y., Nepali, K., Huang, F. I., Chang, C. Y., Lai, M. J., Li, Y. H., Huang, H. L., Yang, C. R. & Liou, J. P., 2月 8 2018, 於: Journal of Medicinal Chemistry. 61, 3, p. 905-917 13 p.

研究成果: 雜誌貢獻 › 文章 › 同行評審

60 引文斯高帕斯（Scopus）

1-Aroylindoline-hydroxamic acids as anticancer agents, inhibitors of HSP90 and HDAC

Ojha, R., Huang, H. L., HuangFu, W. C., Wu, Y. W., Nepali, K., Lai, M. J., Su, C. J., Sung, T. Y., Chen, Y. L., Pan, S. L. & Liou, J. P., 4月 25 2018, 於: European Journal of Medicinal Chemistry. 150, p. 667-677 11 p.

研究成果: 雜誌貢獻 › 文章 › 同行評審

33 引文斯高帕斯（Scopus）

5-Aroylindoles Act as Selective Histone Deacetylase 6 Inhibitors Ameliorating Alzheimer's Disease Phenotypes

Lee, H. Y., Fan, S. J., Huang, F. I., Chao, H. Y., Hsu, K. C., Lin, T. E., Yeh, T. K., Lai, M. J., Li, Y. H., Huang, H. L., Yang, C. R. & Liou, J. P., 8月 23 2018, 於: Journal of Medicinal Chemistry. 61, 16, p. 7087-7102 16 p.

研究成果: 雜誌貢獻 › 文章 › 同行評審

49 引文斯高帕斯（Scopus）

A novel dual HDAC6 and tubulin inhibitor, MPT0B451, displays anti-tumor ability in human cancer cells in vitro and in vivo

Wu, Y. W., Hsu, K. C., Lee, H. Y., Huang, T. C., Lin, T. E., Chen, Y. L., Sung, T. Y., Liou, J. P., Hwang-Verslues, W. W., Pan, S. L. & HuangFu, W. C., 3月 13 2018, 於: Frontiers in Pharmacology. 9, MAR, 205.

研究成果: 雜誌貢獻 › 文章 › 同行評審

開啟存取

22 引文斯高帕斯（Scopus）

Correction: 2-Aroylquinoline-5,8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (HSP90) inhibition (Org. Biomol. Chem. (2016) 14 (716-723))

Nepali, K., Kumar, S., Huang, H. L., Kuo, F. C., Lee, C. H., Kuo, C. C., Yeh, T. K., Li, Y. H., Chang, J. Y., Liou, J. P. & Lee, H. Y., 1月 1 2018, 於: Organic and Biomolecular Chemistry. 16, 25, p. 4734 1 p.

研究成果: 雜誌貢獻 › 文章 › 同行評審

Dual inhibition of PIK3C3 and FGFR as a new therapeutic approach to treat bladder cancer

Chen, C. H., Changou, C. A., Hsieh, T. H., Lee, Y. C., Chu, C. Y., Hsu, K. C., Wang, H. C., Lin, Y. C., Lo, Y. N., Liu, Y. R., Liou, J. P. & Yen, Y., 3月 1 2018, 於: Clinical Cancer Research. 24, 5, p. 1176-1189 14 p.

研究成果: 雜誌貢獻 › 文章 › 同行評審

37 引文斯高帕斯（Scopus）

Novel microtubule inhibitor MPT0B098 inhibits hypoxia-induced epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma

Tsai, I. T., Kuo, C. C., Liou, J. P. & Chang, J. Y., 3月 28 2018, 於: Journal of Biomedical Science. 25, 1, p. 28 28.

研究成果: 雜誌貢獻 › 文章 › 同行評審

10 引文斯高帕斯（Scopus）

The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells

Tu, H. J., Lin, Y. J., Chao, M. W., Sung, T. Y., Wu, Y. W., Chen, Y. Y., Lin, M. H., Liou, J. P., Pan, S. L. & Yang, C. R., 12月 29 2018, 於: Clinical Epigenetics. 10, 1, 162.

研究成果: 雜誌貢獻 › 文章 › 同行評審

21 引文斯高帕斯（Scopus）

劉 景平

研究成果

搜尋結果

劉景平